Comparative Pharmacology
Head-to-head clinical analysis: OGESTREL 0 5 50 21 versus SIMPESSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OGESTREL 0 5 50 21 versus SIMPESSE.
OGESTREL 0.5/50-21 vs SIMPESSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of norgestrel and ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; alters cervical mucus and endometrial lining.
Simpesse is a combination estrogen-progestin oral contraceptive that suppresses gonadotropin release, primarily inhibiting ovulation via negative feedback on the hypothalamic-pituitary-ovarian axis. Additionally, it alters cervical mucus viscosity and endometrial receptivity.
One tablet (norgestrel 0.5 mg / ethinyl estradiol 0.05 mg) orally once daily for 21 days, followed by 7 placebo days.
Oral: 10 mg once daily, taken at least 1 hour before a meal.
None Documented
None Documented
Norgestrel: 24-32 hours; Ethinyl estradiol: 7-12 hours. Clinical context: Steady state achieved after 5-7 days.
Terminal elimination half-life is 24 hours (range 20-28 hours), supporting once-daily dosing.
Renal: ~50% (metabolites); Fecal/Biliary: ~50% (metabolites); <1% unchanged in urine.
Renal excretion of unchanged drug accounts for approximately 60-70% of elimination; hepatic metabolism produces inactive metabolites that are excreted renally (20-30%) and fecally (<10%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive